# **Missouri Cancer Registry**

October 1, 2023

Fellow Registrars,

Happy Fall! I hope you are enjoying the cooler temperatures. The MCR team is actively preparing for the annual Call for Data. If you have not finished submitting 2021 and 2022 cases, please do so as soon as possible.



October is breast and liver cancer awareness month. The attached one-pager provides some stats on breast cancer in our state.



# **DUE DATES**

To be on track, large hospitals (>500 cases/yr.) typically would be expected to have abstracted March 2023 diagnosis cases by October 15, 2023. Smaller facilities (<300 cases /yr.) are expected to report the 1st Quarter of 2023 by October 15, 2023.

#### **EDUCATION**

#### MCR Help-Line

Reach us at 1-800-392-2829 during regular office hours or leave a message; a member of our QA team will return your call within one business day.

## FlccSC-New Course Available!

Earn 3 CE's

NAACCR Webinar – Coding Pitfalls 2023 presented September 2023

## **NAACCR Webinars:**

NAACCR Webinar: Lung 2023 part 1

October 5, 2023, 8-11 a.m., Part 1 of the Lung webinar will focus on treatment of lung cancer. We will discuss the surgery, lymph node related data items, systemic treatment, and radiation. To attend the live broadcast in Columbia, Mo, sign up here: https://www.signupgenius.com/go/30E0E4BA9A823A6FB6-44444961-naaccr#/

## Visitor Parking at Parking Structure 7 (PS7) for NAACCR Webinars

Only those with a valid PS7 visitor permission pass will be allowed to park there. A daily visitor permit is \$7 for parking in lots and \$9 for parking garages. Violators are subject to ticketing and towing. You can purchase a visitor pass online at <a href="https://missouri.nupark.com/v2/Portal/Login">https://missouri.nupark.com/v2/Portal/Login</a>

## Fundamentals of Abstracting Workshop – Winter 2023

MCR is hosting an on-line Fundamentals of Abstracting course beginning December 1, 2023, to be taken at your own pace through January 15, 2024. This class is geared toward new abstractors who are not familiar with the abstracting process. If you are not familiar with abstracting and/or the required fields, this is a great place to start learning. Students will view fifteen pre-recorded **Voice Thread** presentations of the Missouri Cancer Registry Abstract Code Manual at their own pace. When completed with the **Voice Thread** presentations students can work through five practice cases using the Missouri Cancer Registry and Research Abstract Code Manual. The cost of the course is \$50 and will be available on the University of Missouri Canvas platform. You can register for this course by using the following Sign-up Genius link. https://www.signupgenius.com/go/30E0E4BA9A823A6FB6-44447458-fundamentals

# Registration is due by November 30, 2023

## **SEER Educate**

More Mash-Ups released on primary site of the **Gallbladder**, **Major Salivary Gland**, **Penis**, and **Perihilar Bile Duct**. These are the final 4 primary sites that make up the "Mash-up" coding practice series. This series is intended to assess the coding accuracy for the Dx year 2021-2023 changes to EOD, Summary Stage, Grade, and SSDI. Free Category A CEs available for this release.

Log in or sign up at SEER\*Educate today by visiting https://educate.fredhutch.org/ and Learn by Doing!

#### YouTube

## **Surgery of Primary Site 2023+**



New video on YouTube by Lucinda Ham, RHIA, CTR. This video covers the basics of coding surgery in first course of treatment, timing when no treatment plan documented, and where to find resources for coding Surgery of Primary Site. This course has multiple site-specific case scenarios on the changes in coding surgery starting with cases diagnosed in 2023 forward. Sites discussed are bladder, lung, and melanoma of the skin. Examples show entry of multiple surgical procedures. Watch the recording on YouTube at: https://www.youtube.com/watch?v=19hy\_zy8wuM

#### **SEER Educate Training Modules**

The goal in SEER\*Educate, should you incorrectly answer a multiple-choice question, is to explain the broad concept(s) that applies in the rationale. The explanations in the rationale will help your understanding of the material. DO NOT FOCUS on the scores in SEER\*Educate but rather focus on your understanding of the rationales. Log in or sign up at SEER\*Educate today by visiting https://educate.fredhutch.org/ and Learn by Doing! New material is now available.

# 2023 SEER Advanced Topics for Registry Professionals Workshop: December 5-7, 2023

The 2023 SEER Advanced Topics for Registry Professionals Workshop is open to ALL cancer registrars and will be held virtually on Tuesday – Thursday, December 5-7, 2023, 12:00pm-4:30 pm Eastern time. There will be presentations from subject matter experts including surgeons, pathologists, and oncologists.

The workshop is complimentary, but registration is required. Registration for the workshop will go live on October 3rd and close on November 20th. The registration link and agenda will be available through NCRA's website under the Education menu tab. Registration for the workshop will be live on October 3<sup>rd</sup>.

#### **ABSTRACTING TIP**

## **Testis Stage**

- Code Summary Stage 1 (localized only) for tumors WITHOUT lympho-vascular invasion (LVI) (code 0)
- Code Summary Stage 2 (Regional by direct extension only) if lympho-vascular invasion (LVI) is positive (codes 1-4)
- Code Summary Stage 4 (Regional by BOTH direct extension (lympho-vascular invasion (LVI) positive (codes 1-4) AND regional lymph node(s) involved)

**Multiple myeloma** (histology 9732). Summary Stage 2018 Manual instructs that histology 9732 is always coded 7 (Distant) for systemic involvement.

**Plasma Cell Myeloma** also requires code 7 (Distant). Codes 7 or 9 are allowed for a DCO reporting source.

**Hematopoietic malignancies**. Summary Stage 2018 Manual instructs that histologies listed below are always coded 7 (Distant) for systemic involvement.

Codes 7 or 9 are allowed for a DCO reporting source.


Histology is 9591,9671,9727,9740-9742,9761-9762,9800-9801,9806-9809,9811-9818,9820,9831-9834,9837,9840,9860-9861,9863, 9865-9867,9869-9879,9891,9895-9898,9910-9912,9920,9931,9940,9945-9946,9948,9950,9961-9968,9975,9980,9982-9983,9985-9986, 9989,9991-9993.

#### **DEATH CLEARANCE**

The annual Death Clearance activities for reporting year 2021 are underway. If you received an email notification requesting follow back information from your facility, please log into Web Plus and relay any information that you may have to help us clear the case. We appreciate your contributions in making this process successful, and it is an essential part for MCR to meet our annual goals!

If you are new to the process or would like a refresher, please refer to the written instructions found on the MCR website at

https://medicine.missouri.edu/sites/default/files/MCR/MCR Death Clearance Followback Detailed Instructions.pdf



Kirsten McDowell, CTR, created this YouTube which provides video instructions on processing Death Clearance cases.

https://www.youtube.com/channel/UCsm Eu4-pqldZibqeyOecUQ

## MCR NEWS

V23 Cases - MCR is accepting 2023 cases!

## **NEWS FROM THE STANDARD SETTERS**

## **2024 ICD-O Update and Guidelines**

The 2024 Guidelines for ICD-O-3 Histology Code and Behavior Update for cases diagnosed 1/1/2024 forward have been released and are now available on the NAACCR website. The update includes tables listing new codes, terminology, and

behavior changes and is available in .pdf format. The update also includes the annotated ICD-O-3.2. Excel document. The 2024 documents are available at: https://www.naaccr.org/icdo3/

## **NCRA - New CTR Credential Announced**

The National Cancer Registrars Association (NCRA) and its Council on Certification have updated the credential name of CTR, Certified Tumor Registrar, to **ODS**, **Oncology Data Specialist**. The new name better aligns with the evolving scope of practice of cancer registrars and current professional practice terminology. The use of the new credential begins January 1, 2024; NCRA anticipates the adoption will take at least a full calendar year.

CTR credential holders are encouraged to wait until January 1, 2024, to use the new credential.

## **NCRA Membership**

NCRA Membership Renewal is available now! Members who renew by September 30 will receive complimentary access to 1 online continuing education learning module on the Center for Registry Education (CCRE). A great way to earn one free CE by December 31, 2023! https://bit.ly/3zfZGnn

## **NCRA Education**

NCRA's three-part fall webinar series focuses on Pancreatic Neuroendocrine Tumors, Coding Biopsies and Biliary tract cancers. Earn one CE credit per webinar. All webinars at 2:00 PM ET. Learn more and register today! <a href="https://www.cancerregistryeducation.org/live-webinars">https://www.cancerregistryeducation.org/live-webinars</a>



# **SEER - Cancer PathCHART**

The Cancer Pathology Coding Histology and Registration Terminology (Cancer PathCHART) initiative has released the 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List (CPC SMVL). These tumor site-morphology combination standards for cancer surveillance in North America can be freely downloaded today by cancer registration software vendors and other end users at <a href="https://seer.cancer.gov/cancerpathchart/products.html">https://seer.cancer.gov/cancerpathchart/products.html</a>. The four easily consumed, computer-readable file formats are CSV, XLSX, XML, and JSON. The 2024 CPC SMVL replaces both the ICD-O-3 SEER Site/Histology Validation List and the list of impossible site and histology combinations included in the Primary Site, Morphology-Impossible ICDO3 (SEER IF38) edit.

#### REGISTRY TO RESEARCH

In Situ, Invasive Melanoma Diagnoses Decreased in 2020 (SEER) <u>Incidence of In Situ and Invasive Cutaneous Melanomas</u>

During the COVID-19 Pandemic in the US | Dermatology | JAMA Dermatology | JAMA Network

Racial Disparities in Treatment and Outcomes Between Non-Hispanic Black and Non-Hispanic White Women With Nonmetastatic Inflammatory Breast Cancer (SEER) Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer | SpringerLink

# **RESOURCES AND ITEMS OF INTEREST**

Real-World Outcomes of Patients with Multiple Myeloma Receiving Ide-Cel After Prior BCMA-Targeted Therapy <a href="https://www.nature.com/articles/s41408-023-00886-8">https://www.nature.com/articles/s41408-023-00886-8</a>

# HER2-Low Expression in Patients With Advanced or Metastatic Solid Tumor

https://www.practiceupdate.com/c/156164/2/1/?elsca1=emc\_enews\_daily-

<u>digest&elsca2=email&elsca3=practiceupdate\_onc&elsca4=oncology&elsca5=newsletter&rid=NTEyMjg3Njg4NDY0S0&lid=20844069</u>

# AACR Cancer Progress Report Reveals 33 Percent Decrease in Cancer Death Rate, 1990 to 2020

https://www.practiceupdate.com/c/156766/2/1/?elsca1=emc\_enews\_daily-

digest&elsca2=email&elsca3=practiceupdate\_onc&elsca4=oncology&elsca5=newsletter&rid=NTEyMjg3Njg4NDY0S0&lid =20844069

Warm regards,

# Lucinda Ham, RHIA, CTR

QA Manager, Missouri Cancer Registry

**Department of Public Health** 

**1095 Hospital Drive** | Columbia MO 65211

**O:** 573-882-7775 | **C:** 573-220-2438

F: 573-884-9655 | E: lahf5p@health.missouri.edu
W: https://umurl.us/missouri-cancer-registry

College of Health Sciences
University of Missouri

"The only impossible journey is the one you never begin" – Tony Robbins

Missouri Cancer Registry and Research Center is supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (DP2202-22-02) and a Surveillance Contract between DHSS and the University of Missouri.